Shares of Gilead Sciences Inc. /zigman2/quotes/210293917/composite GILD +0.38% were down 1.6% in premarket trading on Monday after the drugmaker released findings from a late-stage clinical trial testing remdesivir in moderately ill COVID-19 patients. Gilead had previously released data from a similarly-run open-label Phase 3 trial evaluating remdesivir in severely ill COVID-19 patients, as well as another Phase 3 trial run by the National Institute of Allergy and Infectious Diseases that found the drug could reduce the time to recovery in severely ill patients. That study's findings led to an emergency use authorization for remdesivir last month. The latest trial showed that moderately ill patients taking a five-day regimen of the drug were 65% more likely to demonstrate clinical improvement, compared to those receiving the standard of care. Patients taking the 10-day regimen did not report a statistically significant improvement. Gilead's stock is up 19.8% year-to-date. The S&P 500 /zigman2/quotes/210599714/realtime SPX +0.45% is down 5.7%.